QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Exclusion Criteria

• •1. History of invasive malignancies within 5 years prior to signing the informed consent form, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix;
• •2. Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months;
• •3. Stage IV metastatic breast cancer;
• •4. Administration of a vaccine within 30 days before the first dose of the study treatment;
• •5. Subjects with severe systemic diseases;
• •6. Subjects with active infections (including but not limited to HIV, hepatitis B or C, tuberculosis);
• •7. Severe cardiovascular diseases, such as: history of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the past 6 months; or congestive heart failure (CHF) of New York Heart Association (NYHA) class II-IV, or history of CHF NYHA class III or IV;
• •8. Lactating women should discontinue breastfeeding during the study;
• •9. Subjects with known allergies to the study drug or any of its excipients;
• •10. Any other condition deemed inappropriate for participation in the study by the investigator.
• •\-